These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 2499248)
1. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248 [TBL] [Abstract][Full Text] [Related]
2. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis. Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256 [TBL] [Abstract][Full Text] [Related]
3. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Golper TA; Hartstein AI; Morthland VH; Christensen JM Antimicrob Agents Chemother; 1987 Nov; 31(11):1787-90. PubMed ID: 3435126 [TBL] [Abstract][Full Text] [Related]
4. Altered disposition of fleroxacin in patients with cystic fibrosis. Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis. Uehlinger DE; Schaedeli F; Kinzig M; Sörgel F; Frey FJ Antimicrob Agents Chemother; 1996 Aug; 40(8):1903-9. PubMed ID: 8843301 [TBL] [Abstract][Full Text] [Related]
6. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers. Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955 [TBL] [Abstract][Full Text] [Related]
7. The metabolism and pharmacokinetics of fleroxacin in healthy subjects. Griggs DJ; Wise R; Kirkpatrick B; Ashby JP J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537 [TBL] [Abstract][Full Text] [Related]
9. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients. Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257 [TBL] [Abstract][Full Text] [Related]
10. Single and multiple dose pharmacokinetics of fleroxacin. Weidekamm E; Portmann R; Partos C; Dell D J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533 [TBL] [Abstract][Full Text] [Related]
11. Comparative oral pharmacokinetics of fleroxacin and pefloxacin. De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532 [TBL] [Abstract][Full Text] [Related]
13. Renal handling of fleroxacin in rabbits, dogs, and humans. Shiba K; Saito A; Shimada J; Hori S; Kaji M; Miyahara T; Kusajima H; Kaneko S; Saito S; Ooie T Antimicrob Agents Chemother; 1990 Jan; 34(1):58-64. PubMed ID: 2109576 [TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788 [TBL] [Abstract][Full Text] [Related]
15. Quinolone pharmacokinetics and metabolism. Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fleroxacin in renal impairment. Weidekamm E Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185 [TBL] [Abstract][Full Text] [Related]
17. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin. Kampf D; Schurig R; Weihermüller K; Förster D Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers. Sorgel F; Metz R; Naber K; Seelmann R; Muth P J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534 [TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. Fleming LW; Moreland TA; Scott AC; Stewart WK; White LO J Antimicrob Chemother; 1987 Apr; 19(4):493-503. PubMed ID: 3583969 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens. Panneton AC; Bergeron MG; LeBel M Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]